The importance of cholinergic influences on growth hormone (GH) secretion has recently been established. The purpose of this study was to investigate the effect of low and high dose atropine (specific muscarinic cholinergic inhibition) on tlie normal secretion of GH. Nocturnal secretion was established by sampling frequently during the first cycle of Stage IV sleep in 9 subjects. Atropine was administered orally in a dose of 0.6mg (n = 5) or 1.6mg (n = 4) 30 mins before expected sleep and the sampling repeated. The peak GH level without atropine was 38.5 mU/1 (range 6.7 to 92.0) while both doses of atropine completely inhibited GH secretion.
O.WESTPHAL, K.ALBERTSSON WIKLANP,Dept. of Paediat I1 East Hospital, GBteborg, Sweden. Secretory pattern of growth hormone (GH) in tall girls treated with Ethinyloestradiol(0e)or Bromocriptine(B). To investigate GH dynamics in tall girls an integrated 24hG~-anal~sis has been performed in 12 tall pubertal girls collecting a sample every 20 min using a Kowarski-Cormed pump.The effect of Oe 500 ug daily (5pat) or B 5-7,s mg(7pat) on spontaneous GH secretion has been studied by repeating the 24h analysis. On Oe treatment every girl increased the area under the curve, mean peak amplitude and the GH-level between peaks, so but less pronounced, did 4 out of 5 patients on B. On Oe the number of peaks was unchanged, on B slightly reduced. Somatomedin A (K.Hal1) decreased during Oe-therapy, data yet not available on B. Growthrate was reducedduring Oe, unchanged on B treatment. The growth inhibiting effect of Oe is not mediated by GH but by SM and by acceleration of bone age. Effects of androgens on erythroid colony formation in children bone marrow cultures. We studied the role of androgens on children erythropoietic precursors cells in culture. Cultures of normal marrow from surgical intervention (informed consent) were carried out using a miniaturized methyl-cellulose method in the presence of erythropoietin (11U/ml). Effects of testosterone (T), 5 -dihydrotestosterone (DHT) and nor-testosterone (nor-T) were evaluated on colony forming units erythroid (CFU-E) after 7days of incubation at 37OC CFU-E were quantified by scoring directly colonies and by a biochemical determination of the uroporphyrinogen I synthaseactivity (UROS). Results are given as number of CFU-E per 32.000 nucleated cells plated. UROS activity is expressed as pmoles of uroporphyrinogen formed per hour and per well. CFU -UROS (mean+SD) Controls (n=6) 2 7 3 7 3 6 17 1 -1 (Takahashi et al. Mol. Cell Endocr. 35:15,1984) .The purpose of the present work was 1)to determine wether such cartilage cells contain specific binding sites for DHT 2)to study the variation of the 5areductase activity at different ages from birth to post puberty.The 3~-DHT and 3~-~1 8 8 1 binding studies were performed in total cartilage cell proteins prepared in 0.4 M KC1 Tris buffer.After two hours incubation at15' bound and free binding sites were separated by charcoal or PEG adsorption and analyzed by Scatchard plots.The binding capacity was 2-7 pmoles/mg protein with low affinity ( K D = o .~-~x~o -~~M )
.The cartilage Sareductase activity was studied by incubating AR cartilage slices in the presence of 3~-T (90 nM).Radiolabelled steroids were then extracted from tissue and incubation medium, analysed by celite chromatography and the amount of newly formed 3~-DHT was quantified.During the first 10 days after birth, AR cartilage 5a reductase activity was 3.55+1.05 pmoles/mg tissue.It increasedpm gressively to reach 51.5f2.5 pmoles/mg tissue in 20 to 50 day old animals and then came down to the starting levels. The maximum m tivity thus observed at puberty when androgen plasmatic concentration rises in male rabbits could be related to variations in an* gen receptors.
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Effect of Delta-1-Testololactone(DT) in boys with pubertal gynecomastia(PG) .
7 Boys with PG(mean age 15.4+l.lyrs),and 1 man (23yrs)with persistent G were treated with oral DT 450mgId for 1.5 to 6 (mean 3.2)months without side-effects.In 2, PG disappeared after 3 and 4 months of DT,in 1 of them,it reappeared 6 months after discontinuation.In 5 others,glandular tissue became softer and/or smaller,and in 1, DT had no effect.Testicular volume did not change.The following steroid changes were observed: basal on DT P . ., -. 'ug/l(a),and~~~~ 206~i25m~/l.~ltho;~h clinical'rksults are variable and difficult to evaluate,it is concluded that DT might be useful in PG by increasing the androgenlestrogen ratios. Supported by the Swiss National Science Foundation (Grants No.
3. 959-0.80,3.874-0.83,and 3.984-0.80 Usefulness of urinary GB-hydroxycortisol (GBOHF) excretion in the diagnosis of Cushing's syndrome. Rapid and simple laboratory diagnosis of cortisol excess due to Cushing's syndrome is highly desirable. To date chronic overproduction of cortisol and loss of diurnal cortisol variation are considered to be the most consistent metabolic abnormalities in Cushing's syndrome. Nevertheless free urinary cortisol (F) and plasma cortisol levels may yield false negative results. We there fore applied a recently developed RIA for 6BOHF. 6BOHF is the major unconjugated urinary metabolite of corticol. In the evaluation of 33 adolescents and young adults for Cushing's syndrome near normal 170H corticosteroids ( 14mg/24h) and/or F ( 120pg/24h) were found in 6 patients. 6BOHF was at least 10 times above nl in all 33 patients (mean:8.11mg/24+2.01 (SE) mg/24h vs nl 0.405.1 mg/24h). The ratio of ~BOHF/F was also markedly elevated (mean 14,8+3.3; vs nl 6.751). The highest 6BOHF excretion was seen in patients with ectopic ACTH production and adrenal cancer (35 and 75mg/24hr respectively). 6BOHF proved to discriminate better than either 170H corticosteroids or F; no false negative or positive cases were seen in the present series. Our data suggest that excess ACTH indirectly and corticol directly induce 60-hydroxylase activity causing highly diagnostic increases in 6BOHF excretion. Measurement of urinary 60OHF is therefore suggested as a new, clinically useful test in the evaluation of hypercortisolemic states.
